Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2022-04-18 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder, including detailed tables of shareholding and pledge status. It does not contain financial statements, management discussion, or report content. It is a regulatory disclosure about share pledging, which fits the category of Major Shareholding Notification (MRQ) as it involves significant share ownership changes and pledges by a major shareholder. The document length is short and focused on share pledge details, not a full report or announcement of a report publication.
2022-04-18 Chinese
关于回购注销部分限制性股票通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the repurchase and cancellation of part of its restricted stock under the 2019 restricted stock incentive plan. It details the board resolutions, the number of shares to be repurchased and cancelled, the impact on total share capital, and a notification to creditors about their rights to demand debt repayment or provide guarantees within 45 days. The document is a formal notice to creditors about the company's stock repurchase and capital reduction, not a financial report or earnings release. It is not a report itself but an announcement related to a capital change event. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is short (1572 characters), and it contains detailed information about the capital change event, not just a brief notification or a report publication announcement. Hence, the classification is SHA with high confidence.
2022-04-18 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 Annual General Meeting (AGM) of Tianjin Ruipu Biotechnology Co., Ltd. It includes voting results on various proposals such as the 2021 annual report, board and supervisory reports, audited financial statements, profit distribution plan, and other corporate matters. The document also mentions the meeting procedures, attendance, and legal opinions confirming the validity of the meeting. There is no actual financial data or full report content included, only the voting results and meeting details. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA) rather than the full Annual Report (10-K) or AGM Information presentation (AGM-R). The document length is about 4561 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2022-04-18 Chinese
关于取得兽药产品批准文号的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of veterinary drug product registration numbers by the Ministry of Agriculture and Rural Affairs. It details product specifications, approval numbers, and the significance of these approvals for the company's product line and market position. The document is short (2091 characters) and does not contain financial data, management discussion, or regulatory certifications. It is an announcement of regulatory approval for products, not a financial report or management update. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-04-11 Chinese
2021年年度报告（更新后）
Annual Report Classification · 100% confidence The document is titled "天津瑞普生物技术股份有限公司 2021 年年度报告全文" which translates to "Tianjin Ringpu Biotechnology Co., Ltd. 2021 Annual Report Full Text." It contains detailed sections such as company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, shareholding changes, bond information, and a full financial report section. The length is substantial (15,000 characters), and the content includes comprehensive financial and operational data for the full fiscal year 2021. There is no indication that this is merely an announcement or a summary; rather, it is the full annual report document. Therefore, the appropriate classification is Annual Report (10-K). FY 2021
2022-03-31 Chinese
关于2021年年度报告的更正公告
Regulatory Filings Classification · 95% confidence The document is titled as a correction announcement related to the 2021 Annual Report of Tianjin Ruipu Biotechnology Co., Ltd. It explicitly states that it is a correction to the previously published 2021 Annual Report and details corrections to the environmental and social responsibility section. The document length is 4508 characters, which is relatively short and mainly focuses on correcting previously disclosed information rather than presenting the full annual report itself. It also states that the corrected annual report is published simultaneously on the designated information disclosure media, indicating this document is an announcement of corrections rather than the full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a correction announcement and does not contain the full annual report or substantive financial data itself.
2022-03-31 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.